PDB28: DEVELOPMENT OF AN INSTRUMENT TO MEASURE PATIENT EXPECTATION AND PREFERENCE FOR THE INSULIN INJECTION PEN  by Szeinbach, SL et al.
337Abstracts
tionnaire (Norfolk QOL) previously constructed using
the Delphi method to inventory neuropathy subscales:
symptoms, involvement of small, large, autonomic nerve
ﬁbers, and activities of daily living (ADL). METHODS:
We studied 242 subjects comprising three groups: 75
healthy control (C); 86 diabetic control without neu-
ropathy (DC); and 81 diabetic patients with peripheral
neuropathy (DN). The questionnaire was administered to
all three groups and repeated at 1–3 month intervals to
determine scores, reliability and reproducibility. One-way
analysis of variance (ANOVA) and Tukey-Kramer post
hoc (= 0.05) tests were used to compare the different
groups and Cronbach alpha coefﬁcients of internal con-
sistency and intra-class correlation coefﬁcients (ICC) to
test reproducibility. RESULTS: Overall the DN group
(39.8 ± 3.3) scored 3–4 fold higher than DC (12.8 ± 1.5)
and 6–10 fold higher than C (5.8 ± 1.0). Scores for each
subscale were <1–5.1 in C and 1.3–11.2 in DC whereas
DN scores were: autonomic 4.0 ± 0.3; small ﬁber 8.3 ±
0.7; large ﬁber 11.3 ± 1.1 and ADL 31.6 ± 2.8 (p < 0.05
for all). DC scored higher than C because of urinary 
problems in females and erectile dysfunction in non-
neuropathic males. ADLs were worse in DC because of
diabetes and its complications other than neuropathy
accounting for the feeling of accomplishing less. All items
met the requirements of a Cronbach alpha coefﬁcient of
internal consistency >0.5 and ICC r > 0.9. CONCLU-
SIONS: The Norfolk QOL domains and individual items
are reproducible in all groups. This instrument is sensi-
tive and speciﬁc for the different features of diabetic neu-
ropathy and has the capacity for providing non-invasive
clinical guidelines for assessing disease impact and for
evaluating responses to treatment.
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OBJECTIVE: The purpose of this study is to quantify and
compare diabetes patient preferences for short-term treat-
ment outcomes and the number insulin injections among
Type 2 patients in the US and Canada. METHODS: A
total of 1931 subjects with Type 2 diabetes completed a
stated-preference questionnaire that included a series of
12 hypothetical treatment choices. Each treatment alter-
native speciﬁed the number of daily insulin injections,
fasting plasma glucose (FPG), glycated hemoglobin
(HbA1c), number of hypoglycemic events per month, and
monthly cost of treatment. RESULTS: Patients in both the
US and Canada place signiﬁcant value on reducing the
number of daily insulin injections and improving glucose
control. US patients value avoiding an increase from 1
injection to 2 injections at about US$60 per month. 
Canadian patients value avoiding the same change in
injections at about 60% lower at US$25. Both US and
Canadian patients value improving their current glucose
control to the best level as equivalent to an income gain
of about $30 per month. CONCLUSIONS: Type 2 dia-
betes patients in both the US and Canada value better
glucose control and fewer injections. Canadian patients
value improved control more than fewer injections. In
contrast, US patients value fewer injections almost twice
as much as improved control. While all patients are
willing to sacriﬁce glucose to avoid injections, US patients
are more likely than Canadian patients to do so. Insulin
delivery devices that reduce the burden of injections are
likely to be preferred by Type 2 patients. Given the serious
long-term health risks associated with poor glucose
control, less burdensome insulin delivery methods that
also result in greater compliance have the potential to
improve long-term health outcomes among Type 2
patients.
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OBJECTIVES: As insulin delivery products evolve, it
becomes important to identify patients’ expectations
about these products to satisfy their perceived needs. The
purpose of this study was to develop a self-administered
questionnaire for use in subsequent evaluations of expec-
tations and satisfaction with an insulin injection pen.
Expectations of products and subsequent experience lead
to consumers’ satisfaction and other outcome measures.
In this phase of instrument development a closely related
notion, preference, was used as a surrogate for satisfac-
tion since the data were collected prior to product expe-
rience. METHODS: Development of the instrument
included item generation, item reduction and analysis to
assess reliability and validity. A questionnaire consisting
of 49 items was generated for the initial phase of this
study. Using an expert panel and focus groups, items were
evaluated for content and face validity to ensure they ade-
quately represented expectations. The sample consisted of
1500 United States residents randomly selected from a
mail address database containing respondents known to
have types 1 or 2 diabetes. We used a single mailing, 
consisting of a cover letter, data collection instrument 
and return envelope. RESULTS: The response rate was
20.4%. Kaiser-Meyer-Olkin (KMO) Measure of Sam-
pling Adequacy for the ﬁnal principal components analy-
sis was 0.92. Bartlett Test of Sphericity was signiﬁcant
(.0001), indicating the appropriate use of exploratory
factor analysis. Item reduction was accomplished by
examining item-to-total correlations and factor loadings.
Oblique rotation was used to obtain a ﬁnal factor solu-
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tion consisting of three dimensions, which explained
73.6% of the variance. Cronbach’s alpha was 0.92 for the
13 ﬁnal items. CONCLUSIONS: The subscales: ease of
use (a = 0.91), activity interference (a = 0.86), and social
acceptability (a = 0.82) relating to expectations satisﬁed
the criteria for scale reliability and validity. Subsequent
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OBJECTIVES: Anemia occurs in approximately 75–95%
of patients admitted to the ICU for at least 3 days and is
associated with lengthened intensive care unit (ICU) stay
and increased mortality. However, red blood cell (RBC)
transfusion is also associated with deleterious effects and
may increase mortality. The objective of this analysis was
to examine the cost-effectiveness of using recombinant
human erythropoietin (rHuEPO) to prevent or reduce the
use of RBC transfusions in a mixed (medical/surgical/
trauma) ICU. METHODS: The authors used decision
analysis to examine the immediate and lifetime costs and
effectiveness of using rHuEPO. The model included: fea-
sibility (the deferral rate for allogeneic RBC transfus-
ions), rHuEPO efﬁcacy (the reduction in allogeneic RBC
use), and adverse effects of rHuEPO and allogeneic 
RBC transfusions. Adverse effects of rHuEPO included
deep venous thrombosis (DVT) and thrombocytopenia.
Adverse effects of RBC transfusion included acute lung
injury (ALI), hemolytic reaction (HR), and febrile reac-
tions (FR) including hepatitis B (HB), hepatitis C (HC),
human immunodeﬁciency virus (HIV), and human T-cell
lymphotrophic virus (HTLV). Effectiveness was measured
using discounted quality-adjusted life years (QALYs).
Costs are expressed in 2002 U.S. dollars using 3% as the
discount rate. Univariate sensitivity analysis was con-
ducted to examine the impact of uncertainty in the para-
meter estimates on the results of the model. RESULTS:
For the base case analysis, the cost-effectiveness of using
rHuEPO to prevent anemia- related RBC transfusions
was $17,806,000/QALY. Results of the sensitivity analy-
ses revealed that the cost and total dose or units trans-
fused of rHuEPO and RBC transfusion had the greatest
impact on the expected cost of therapy. QALY decrements
associated with adverse effects had minimal impact on the
expected effectiveness of treatment. CONCLUSIONS: It
is unlikely that the use of rHuEPO to prevent or reduce
RBC transfusions in a mixed ICU population is cost-
effective.
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OBJECTIVES: Hemophilia A is a rare hereditary bleed-
ing disorder with serious consequences. Replacement
therapy is normally administered, either prophylactically
or on demand. Economic aspects have been little
researched. Therefore, we conducted a cost analysis using
data from the Hemophilia Treatment Centre in London,
Canada, where all patients are treated prophylactically.
METHODS: We reviewed charts of all severe hemophilia
patients (n = 6) from time of diagnosis until the present,
identifying resources consumed, then costing from the
Ministry of Health perspective. Patients having com-
plications, such as inhibitors, HIV, or hepatitis, were
excluded. For each subject, we determined the costs of
Factor VIII, hospitalization, port-A-catheter insertions
and complications, treatments, homecare and physi-
cian/clinic visits, in Canadian 1997 dollars, discounted at
3%. RESULTS: Data were available from 1988 to 1999.
The total average cost (range) was $51,994 ($2171–
$75,516)/patient/year. Factor VIII was the major cost
driver [$48,772 ($802–$73,483)] comprising 94%
(37%–97%) of all expenditures. Average hospitalization
cost/patient was $1,190 ($0–$15,877), including surgery,
drugs, nursing care and stay. In total, there were 11 hos-
pitalizations [0.3 (0–1)/patient/year], which lasted 57 hos-
pital days [1.6 (0–8)/patient/year]. Treatment cost per
bleed was $613 ($0–$2875). Patients had 76 bleeds in
total [2.2 (0–14)/patient/year]. Catheter costs were $428
($0–$1975) and complications added $326 ($0–$727),
clinic visits contributed $572 ($484–$723) and home care
added $92 ($0–$371). Total costs increased linearly over
time [yearly cost = $4774.1 per year + $10,307 (r2 =
0.54)], as did Factor VIII cost [yearly cost = $5263 per
year + $3064 (r2 = 0.61)]. CONCLUSIONS: In this series
of severe hemophilia patients, prophylactic treatment was
found to be very expensive at more than $50,000 per
patient. However, the results were sensitive to the clotting
factor unit cost, which comprised 94% of the total
average cost/patient/year. For all patients, a decrease in
number of bleeds, hospitalizations and hospital days 
was observed over time, suggesting increasing quality of
life.
